Terms: = Colorectal cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
111 results:
1. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
[TBL] [Abstract] [Full Text] [Related]
2. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
[TBL] [Abstract] [Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
4. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
[TBL] [Abstract] [Full Text] [Related]
5. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
6. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (mek162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic colorectal cancer.
Van Cutsem E; Yaeger R; Delord JP; Tabernero J; Siu LL; Ducreux M; Siena S; Elez E; Kasper S; Zander T; Steeghs N; Murphy D; Edwards M; Wainberg ZA
Oncologist; 2023 Dec; 28(12):e1209-e1218. PubMed ID: 37597246
[TBL] [Abstract] [Full Text] [Related]
7. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic colorectal cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M; Tabernero J; Grothey A; Arnold D; O'Dwyer PJ; Gilberg F; Abbas A; Thakur MD; Prizant H; Irahara N; Tahiri A; Schmoll HJ; Van Cutsem E; de Gramont A
Eur J Cancer; 2023 May; 184():137-150. PubMed ID: 36921494
[TBL] [Abstract] [Full Text] [Related]
9. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and mek1/2.
Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
[TBL] [Abstract] [Full Text] [Related]
10. Melatonin-Assisted Cisplatin Suppresses Urinary Bladder cancer Cell Proliferation and Growth through Inhibiting PrP
Yang CC; Chuang FC; Chang CL; Huang CR; Chen HH; Yip HK; Chen YT
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834767
[TBL] [Abstract] [Full Text] [Related]
11. The association of blood ctDNA levels to mutations of marker genes in colorectal cancer.
Bai F; Du Q; Zou Q; Xu L; Dong W; Lv X; Han X; Zhou H; Zhang C; Lu T
Cancer Rep (Hoboken); 2023 Apr; 6(4):e1782. PubMed ID: 36746394
[TBL] [Abstract] [Full Text] [Related]
12. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract] [Full Text] [Related]
13. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic colorectal cancer and Other cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
Tan L; Tran B; Tie J; Markman B; Ananda S; Tebbutt NC; Michael M; Link E; Wong SQ; Chandrashekar S; Guinto J; Ritchie D; Koldej R; Solomon BJ; McArthur GA; Hicks RJ; Gibbs P; Dawson SJ; Desai J
Clin Cancer Res; 2023 Mar; 29(6):1017-1030. PubMed ID: 36638198
[TBL] [Abstract] [Full Text] [Related]
14. Cobimetinib Plus Vemurafenib in Patients With colorectal cancer With
Klute KA; Rothe M; Garrett-Mayer E; Mangat PK; Nazemzadeh R; Yost KJ; Duvivier HL; Ahn ER; Cannon TL; Alese OB; Krauss JC; Thota R; Calfa CJ; Denlinger CS; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Nov; 6():e2200191. PubMed ID: 36409971
[TBL] [Abstract] [Full Text] [Related]
15. Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.
Wei XL; Zhang Y; Zhao HY; Fang WF; Luo HY; Qiu MZ; He MM; Zou BY; Xie J; Jin CL; Zhou XF; Wang F; Wang FH; Li YH; Wang ZQ; Xu RH
Oncologist; 2023 Jan; 28(1):e36-e44. PubMed ID: 36398872
[TBL] [Abstract] [Full Text] [Related]
16. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic colorectal cancer.
Topham JT; O'Callaghan CJ; Feilotter H; Kennecke HF; Lee YS; Li W; Banks KC; Quinn K; Renouf DJ; Jonker DJ; Tu D; Chen EX; Loree JM
J Clin Oncol; 2023 Jan; 41(3):485-496. PubMed ID: 36007218
[TBL] [Abstract] [Full Text] [Related]
17. Selumetinib: a selective mek1 inhibitor for solid tumor treatment.
Hedayat M; Jafari R; Majidi Zolbanin N
Clin Exp Med; 2023 Jun; 23(2):229-244. PubMed ID: 35171389
[TBL] [Abstract] [Full Text] [Related]
18. Reckoning apigenin and kaempferol as a potential multi-targeted inhibitor of EGFR/HER2-MEK pathway of metastatic colorectal cancer identified using rigorous computational workflow.
Sharma A; Sinha S; Rathaur P; Vora J; Jha PC; Johar K; Rawal RM; Shrivastava N
Mol Divers; 2022 Dec; 26(6):3337-3356. PubMed ID: 35147860
[TBL] [Abstract] [Full Text] [Related]
19. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
20. The Therapeutic Potential of MAPK/ERK Inhibitors in the treatment of colorectal cancer.
Pashirzad M; Khorasanian R; Fard MM; Arjmand MH; Langari H; Khazaei M; Soleimanpour S; Rezayi M; Ferns GA; Hassanian SM; Avan A
Curr Cancer Drug Targets; 2021; 21(11):932-943. PubMed ID: 34732116
[TBL] [Abstract] [Full Text] [Related]
[Next]
